数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Plasma β-synuclein is a promising blood-based synaptic biomarker, but relationships with synaptic density as indicated by [11C]UCB-J positron emission tomography (PET), and blood biomarkers of Alzheimer's disease (AD) pathology, neurodegeneration, and astrocyte activation need further characterization.
方法
Plasma β-synuclein levels were higher in cognitively unimpaired and impaired participants with positive amyloid PET.；Synaptic density was lower in cognitively impaired participants only.；In the full sample, higher plasma β-synuclein levels associated with lower synaptic density in the hippocampus, higher concentrations of plasma tau markers, and higher plasma GFAP.
核心结论
Primary analyses focused on relationships between plasma β-synuclein and synaptic density, and associations with related plasma biomarkers (tau phosphorylated at threonine 217 [p-tau217], brain-derived tau [BD-tau], glial fibrillary acidic protein [GFAP], and neurofilament light chain [NfL]).；Synaptic density was lower in cognitively impaired participants only.；In the full sample, higher plasma β-synuclein levels associated with lower synaptic density in the hippocampus, higher concentrations of plasma tau markers, and higher plasma GFAP. ‖ 结论：In the full sample, higher plasma β-synuclein levels associated with lower synaptic density in the hippocampus, higher concentrations of plasma tau markers, and higher plasma GFAP.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★★★☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。顶刊证据。
原文题录
- 英文标题：Plasma β-synuclein associates with hippocampal synaptic density measured with [11C]UCB-J PET and plasma tau markers in Alzheimer's disease.
- 期刊与标识：Alzheimers Dement · PMID 42947251 · DOI 10.1002/alz.71900**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。